- Home
- MERC vs CMPX Comparison
MERC vs CMPX Comparison
Compare MERC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- CMPX
- Stock Information
- Founded
- MERC 1968
- CMPX 2014
- Country
- MERC Canada
- CMPX United States
- Employees
- MERC N/A
- CMPX N/A
- Industry
- MERC Paper
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- MERC Basic Materials
- CMPX Health Care
- Exchange
- MERC Nasdaq
- CMPX Nasdaq
- Market Cap
- MERC 271.5M
- CMPX 291.8M
- IPO Year
- MERC 1987
- CMPX N/A
- Fundamental
- Price
- MERC $3.89
- CMPX $2.65
- Analyst Decision
- MERC Hold
- CMPX Strong Buy
- Analyst Count
- MERC 3
- CMPX 9
- Target Price
- MERC $5.33
- CMPX $12.67
- AVG Volume (30 Days)
- MERC 434.8K
- CMPX 797.6K
- Earning Date
- MERC 07-31-2025
- CMPX 08-11-2025
- Dividend Yield
- MERC 7.75%
- CMPX N/A
- EPS Growth
- MERC N/A
- CMPX N/A
- EPS
- MERC N/A
- CMPX N/A
- Revenue
- MERC $1,996,904,000.00
- CMPX $850,000.00
- Revenue This Year
- MERC $2.43
- CMPX N/A
- Revenue Next Year
- MERC $6.12
- CMPX N/A
- P/E Ratio
- MERC N/A
- CMPX N/A
- Revenue Growth
- MERC N/A
- CMPX N/A
- 52 Week Low
- MERC $3.20
- CMPX $0.87
- 52 Week High
- MERC $8.57
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- MERC 58.53
- CMPX 64.52
- Support Level
- MERC $3.52
- CMPX $2.62
- Resistance Level
- MERC $4.04
- CMPX $2.87
- Average True Range (ATR)
- MERC 0.16
- CMPX 0.16
- MACD
- MERC 0.06
- CMPX 0.00
- Stochastic Oscillator
- MERC 76.92
- CMPX 81.03
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.